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Effect of immunosuppressants on OKT3 associated T cell activation:
Clinical implications. The monoclonal antibody directed at the T cell
differentiation antigen T3 (CD3, T.gp 20—25) appears to oe superior to
conventional high—dose steriods in the treatment of rejection in
cadaveric renal graft recipients, Re-rejection episodes and other ad-
verse reactions, probably secondary to T cell activating potential of
anti-T3, continue to be clinical problems with anti-T3 therapy. We
therefore examined the relative efficacy of cyclosporin A (CSA),
methyiprednisolone (MP), or 6-mercaptopurine (6-MP), at concentra-
tions that are readily accomplished in clinical practice, on the activation
of T cells by anti-T3. CSA or MP mediated marked and 6-MP mediated
modest inhibition of anti-T3 induced proliferation of alloimmune mem-
ory T cells. CSA- or MP-inhibited anti-T3 elicited specific secondary
cytolytic activity and natural killer (NK) cell activity, and 6-MP failed
to prevent the augmentation of NK cell activity mediated by anti-T3.
The immunosuppressants also exhibited differential effects on anti-T3-
associated lymphokine production by peripheral blood mononuclear
cells. Interleukin 2 production was completely inhibited by CSA,
modestly inhibited by MP and not inhibited by 6-MP. Interferon gamma
production was completely inhibited by CSA or MP and not inhibited
by 6-MP. Our findings, in addition to providing a plausible immunolog-
ical basis for some of the complications of anti-T3 therapy, provide
experimental support for therapeutic strategies that include the use of
CSA and/or MP along with anti-T3.
The monoclonal antibodies directed at cell surface antigens
expressed on lymphoid cells permit manipulation of the immune
system to an hitherto unaccomplished precision. Indeed, rejec-
tion episodes occurring in recipients of renal allografts have
been successfully treated with rnonoclonal antibodies directed
at the T3 antigen [1—3], T12 antigen [4] or at antigens expressed
on monocytes or blast cells [5]. Of the three monoclonal
antibodies currently under evaluation in clinical transpianation,
the OKT3 (anti-T3) monoclonal antibody has been examined for
its efficacy as an anti-rejection agent in a randomized multicen-
ter clinical trial and an extremely high rate of reversal of
rejection episodes has been reported [3]. Since such successful
reversal of rejection reactions have been associated with re-
rejection episodes (66% incidence [3]) and since anti-T3 can
elicit, in vitro, a variety of immune responses that are poten-
tially detrimental to allograft outcome [6—8], the present inves-
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tigation was focused on the ability of currently used immuno-
suppressants, cyclosporin A, methyiprednisolone or 6-mercap-
topurine (active metabolite of azathioprine) to inhibit potential-
ly—unfavorable immune responses elicited by anti-T3.
Methods
The monoclonal antibody directed at the T3 antigen, OKT3
(anti-T3) was purchased from Ortho Diagnostic System, Inc.,
Raritan, New Jersey, USA. Anti-T3 was initially reconstituted
with one ml of distilled water and then adjusted to appropriate
concentration in RPMI 1640 medium (MA Bioproducts,
Walkersville, Maryland, USA). Methyiprednisolone sodium
succinate (MP) was purchased from Abbott Laboratories
(North Chicago, Illinois, USA) and 6-mercaptopurine (6-MP)
was purchased from Sigma Chemical Company (St. Louis,
Missouri, USA). Cyclosporin A (CSA) was from Sandoz Phar-
maceuticals (E. Hanover, New Jersey, USA). Initial reconsti-
tution of the drugs was accomplished as follows: MP was
dissolved in phosphate buffered saline (PBS); 6-MP was dis-
solved in distilled water and titrated with sodium hydroxide;
CSA was dissolved in ethyl alcohol. RPM! 1640 medium was
then used to obtain the final concentration of MP, 6-MP or
CSA.
Activation with anti-T3 and examination of the effects of
immunosuppressants
Activation of memory cells. Memory cells were generated in
primary long—term MLC's as described previously [71. The
responder cells (memory cells) were collected 10 to 14 days
after initiation of the primary long—term MLC's, were washed
twice with PBS and then suspended in RPM! 1640 medium
supplemented with 100 U/mI penicillin, 100 .tg/ml streptomycin,
25 mrs'i Hepes buffer and 5% heat inactivated, pooled normal
human serum (complete medium). The memory cells were
co-cultured with equal numbers of irradiated syngeneic cells,
with specific allogeneic cells (original priming stimulus) or with
anti-T3. Proliferation was determined by measuring 3H-thymi-
dine incorporation during 48 to 64 hours of culture, and cyto-
toxic activity was assessed in a 5tCr-release assay [7]. Periph-
eral blood mononuclear cells obtained fresh from individuals
whose cells functioned as stimulator cells in the primary
long—term MLC's were labelled with sodium chromate (New
England Nuclear, Boston, Massachusetts, USA) and used as
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Table 1. Effect of immunos
o
uppressants on anti-T3 induced activation
f memory cells
Drugs tested
(ng/ml)
Memory cells co-cultured with
syngeneic allogeneic
cells anti-T3 cells
None
Methyiprednisolone (500)
Methyiprednisolone (1000)
Cyclosporine (250)
Cyclosporine (500)
6-mercaptopurine (100)
613 115 14914 973 12795 1446
323 38 5423 1225 6078 1552
231 34 4372 835 4729 1378
296 45 1074 123 1802 114
345 54 833 110 1024 127
547 hO 9584 898 9670 954
specific target cells. Percent specific 51Cr-release (% SCR) was
calculated using the formula:
% SCR = (Experimental release — spontaneous release)!
(Maximum release — spontaneous release) x 100
Augmentation of natural killer cell activity. Peripheral blood
mononuclear cells (1 x 106 ceils!ml) were incubated with or
without anti-T3 for 16 hours at 37°C in a 5% C02-95% air
atmosphere. At the end of the incubation period, the cells were
retrieved, washed twice and used as effector cells in the
StCrrelease assay, as previously described [7].The T lympho-
blastoid cell line, MOLT-4, was used as the NK-sensitive target
and the assay was established at multiple effector:target ratios.
Dose—response curves generated by plotting percent SCR ver-
sus the number of effector cells were used to compute lytic
units. The number of effector cells needed to lyse 10% of the
target cells was designated as one lytic unit [8].
Induction of cytokine production. Peripheral blood mononu-
clear cells (1 x 106 cells/mi), suspended in complete medium,
were incubated with 50 ng!ml of anti-T3 for 16 hours at 37°C in
a 5% C02-95% air atmosphere. At the end of incubation,
cell—free supernatants were obtained and dialyzed against
RPMI 1640 medium. The cell—free supernatants were screened
for interleukin 2 (IL-2) activity utilizing a IL-2 dependent
cytotoxic T cell line as indicator cells [9], and for interferon
activity, using an assay based on the inhibition of the cytopathic
effect of vesicular stomatitis virus on human WISH amnion
cells [10]. A radioimmunoassay was utilized to characterize the
type of interferon induced by anti-T3. The effects of immuno-
suppressants, MP, CSA or 6-MP on lymphokine production
were determined by supplementation of cultures with indicated
concentrations of drugs at the time of initiation of cultures.
Results
Effect of immunosuppressants on anti-T3 or alloantigen
associated activation of memory cells
Three immunosuppressants, (MP, CSA and 6-MP), currently
used extensively in organ transplantation, were tested for their
ability to inhibit the activation of memory cells by anti-T3 or by
the alloantigen stimulus. Exposure of memory cells to anti-T3
or to specific allogeneic cells (original priming stimulus) re-
Fig. 1. Effect of CSA or MP on the induction of specific secondary
cyto/ytic activity by anti-T3. A Memory cells were activated with
anti-T3 (50 nglml) or with (B) allogeneic cells and the cultures were
supplemented with CSA (250 ng/ml) or with MP (500 ng/ml). Specific
secondary cytolytic activity was determined after 72 hours of culture
using 51Cr-labelled specific allogeneic cells as target cells. Results
(mean SE) from 3 experiments.
suited in extensive proliferation. 3H-thymidine incorporation
increased from 613 115 CPM!culture (mean SE from 6
experiments) to 14914 973 CPM!culture when memory cells
were activated with 50 ng!ml of anti-T3, and to 12795 1446
CPM!culture when memory cells were co-cultured with al-
logeneic cells (Table 1). The addition of MP (500 to 1000 ng!ml)
to anti-T3 supplemented cultures resulted in 60 to 70% inhibi-
tion of proliferation, and CSA (250 to 500 ng!ml) mediated a
more marked suppression (90 to 95%) of anti-T3 induced
proliferation. In contrast, 6-MP (100 ng/mI) mediated modest
(36%) suppression. MP, CSA or 6-MP mediated similar levels of
inhibition when memory cells were activated with specific
allogeneic cells (Table 1).
Since anti-T3 can induce the acquisition of specific secondary
cytolytic activity independent of alloantigen stimulus [8] and
since MP or CSA mediated marked inhibition of proliferation,
the effect of MP and of CSA on the induction of secondary
cytolytic activity initiated by anti-T3 and by the alloantigen
stimulus was examined. As shown in Figure 1, both CSA and
MP markedly inhibited the induction of specific secondary
cytolytic activity resulting from the exposure of memory cells
either to anti-T3 (Fig. IA) or to the specific allogeneic cells (Fig.
1B). Percent SCR increased from 5 2% to 25 3% when
memory cells exposed to 50 ng!ml of anti-T3 were effector cells
and specific peripheral, blood mononuclear cells were target
cells. Addition of 250 ng!ml of CSA resulted in >90% inhibition
of secondary cytolytic activity and 500 ng/mi of MP mediated
similar levels of inhibition. CSA and MP exhibited similar levels
of suppression of cytolytic activity elicited by the alloantigen
stimulus (Fig. lB).
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Memory cells (1 x 106 cells/mI) were co-cultured with syngeneic cells
with or without 50 ng/ml of anti-T3 or with allogeneic cells. Specified
concentrations of MP or CSA or 6-MP were added to the cultures and
3-H-thymidine incorporation into DNA during 48 to 64 hours of culture
was determined. Results (mean SE) from six experiments.
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Fig. 2. Effect of immunosuppressants on the induction of NK cell
activity by anti-T3. Peripheral blood mononuclear cells (0—0) (1 X 106
cells/mI) were cultured with or without 50 nglml of anti-T3 (—R) for 16
hours at 37°C. The effect of 6-MP 100 ng/ml) or CSA (A—A, 250
ng/ml) or MP (—•, 500 ng/ml) on anti-T3 induced NK cell activity was
determined. Percent SCR at different effector:target ratios (A) and lytic
units (B) found with MOLT-4 as target cells are shown. Results (mean
SE) from three experiments.
Effect of immunosuppressants on the induction of NK-cell
activity by anti-T3
In previous studies we found that anti-T3 is a potent inducer
of NK-cell activity [8]. Since NK-cell activity might contribute
significantly to host defense [11] and since NK-cell activity
varies with the clinical status of organ graft recipients [12, 13],
the effect of immunosuppressive agents on the induction of
NK-cell activity by anti-T3 was examined. Results found in
three experiments where the effects of MP, CSA or 6-MP on
anti-T3 induced augmentation of NK-cell activity were exam-
ined are summarized in Figure 2. As shown, NK-cell activity
was markedly inhibited by either CSA (250 nglml) or MP (500
ng/ml) and was unaffected by 6-MP (100 nglml). At every
effector:target ratio tested, anti-T3 augmented NK-cell activity
and CSA or MP prevented such augmentation by anti-T3 (Fig.
2A). The suppression resulting from these agents was clearly
evident when NK-cell activity was expressed as lytic units (Fig.
2B).
Effect of immunosuppressants on anti-T3 induced cytokine
production
Several recent studies have documented the ability of anti-T3
to induce the production of lymphokines such as IL-2 [7, 141
and interferon, gamma [151. Since such lymphokines might
contribute to graft rejection [16—19], we examined the effects of
immunosuppressants on anti-T3 associated production of IL-2
and interferon, gamma. The results from this approach are
shown in Table 2. As expected from previous studies, activa-
tion of peripheral blood mononuclear cells with anti-T3 resulted
in the production of IL-2 and interferon, gamma [7, 14, 15].
More importantly, both CSA and MP mediated marked inhibi-
tion of cytokine production induced by anti-T3. CSA (250
ng/ml) mediated almost complete inhibition of IL-2 and inter-
feron, gamma production, and MP (500 nglml) mediated about
58% inhibition of interleukin 2 production and complete inhibi-
tion of interferon production. As shown in Table 2, 6-MP failed
to inhibit either cytokine production induced by anti-T3. In
Table 2. Inhibition of anti-T3 induced cytokine production by
cyclosporine or methyiprednisolone
Agents testeda
ng/ml
Interleukin 2
CPM/culture1'
Interferon gamma
IU/ml°
None 2143 857" <131
Anti-T3 (50) 7896 1486 53 13
Anti-T3 (50) + 6.MP (100) 10176 2213 76 29
Anti-T3 (50) + CSA (250) 384 79 <13
Anti-T3 (50) ÷ MP (500) 3794 1306 <13
a Peripheral blood mononuclear cells (1 x 10k' cells/mi) were incubat-
ed with 50 ng/ml of anti-T3 and specified concentrations of 6-MP or
CSA or MP for 16 hours at 37°C. Cell—free supernatants were dialyzed
and tested for Interleukin 2 and interferon, gamma activity.b 3H.thymidine incorporated by interleukin 2 dependent cytotoxic T
cell lines during 20 to 24 hours of culture.
lU/mi of interferon, gamma.' Results (mean SE) from three experiments.
additional experiments, preincubation of cells with 6-MP or
higher concentrations of 6-MP (up to 1000 ng/ml) failed to
inhibit anti-T3 induced lymphokine production.
Discussion
Recent studies suggest that the addition of monoclonal anti-
bodies to the therapeutic armamentarium has resulted in higher
rates of reversal of renal allograft rejection—episodes [1—5].
Specifically, anti-T3 monoclonal antibody has been reported to
be extremely effective as an anti-rejection agent [1—3]. In a
prospective, randomized clinical trial [3], anti-T3 reversed 94%
of the rejections that occurred in 63 patients as compared with
a reversal rate of 75% in 60 patients treated with conventional
high—dose steroids. The ability of anti-T3 antibody to modulate
the T3 antigen [201, abrogate the generation of cytotoxic T cells
[21], and inhibit the cytolytic activity of preformed cytotoxic T
cells [22], provide a plausible basis for its reported efficacy. The
additional functional properties of anti-T3, such as T cell
proliferation [6], induction of lymphokine production [7, 14,
15], and augmentation of cytolytic activity [8], can conceivably
compromise its immunosuppressive potential. Indeed, re-rejec-
tion episodes, albeit at rates similar to the ones found with other
modes of anti-rejection therapy, have been observed in patients
treated with anti-T3 [2, 3]. Also, a variety of adverse reactions
including pyrexia, chills, dyspnea, chest pain and tightness,
vomiting, wheezing or nausea have been reported to occur with
the first or second dose of anti-T3 [3]. Five cases of pulmonary
edema including two deaths secondary to respiratory compro-
mise following anti-T3 therapy have also been reported. Fluid
overload and increased capillary permeability secondary to
mediators released by T cells appear to contribute to the
respiratory failure found with anti-T3.
The current investigation was designed to examine the effects
of CSA, MP and 6-MP on anti-T3 associated T cell activation.
Induction of cytolytic activity and the production of lympho-
kines were used as parameters of T cell activation in our study
since previous reports have implicated cytolytically active cells
and lymphokines in graft rejection [23—24]. Cytotoxic T cells
have been detected in the peripheral blood of renal graft
recipients in association with graft rejection [23—34] and cells
with cytotoxic activity have been recovered from irreversibly
rejected allografts [25, 26]. Indeed, Strom et al [251 have shown
6)
a)
0
'a
C.)
C.)
6)
Ca
a)
C.)
6)0
60
50
40
30
20
10
OKT3 mediated cell activation 365
that the cytotoxic activity of graft infiltrating cells correlates
strongly with the histologic grade of cellular rejection. A role
for IL-2 in allograft rejection is suggested by the correlation
found between IL-2 production and graft rejection [19, 27],and
by the observation that systemic administration of IL-2 results
in the rejection of allografts [18, 28]. Additional studies in which
antibodies directed at IL-2 [29] or at the IL-2 receptor [301
abrogate graft rejection also support a role for IL-2 in the
rejection of allografts. In studies reported here, we also exam-
ined the production of interferon, gamma since it can upregulate
the expression of major histocompatability complex (MHC)
antigens [17, 31, 32].
While it is clear that cytolytically active cells and lympho-
kines can contribute to graft rejection, it is not known at this
stage whether anti-T3 elicits cytolytic activity and lymphokine
production in vivo. The observations that anti-T3 induces
antibody production in vivo [30] and immunoblasts are found in
lymph node biopsies following anti-T3 therapy [351, indeed
suggest that anti-T3 can activate cells in vivo. It is noteworthy
in this context that the first or second dose of anti-T3 is
associated with a symptom complex that is reminiscent of
adverse reactions reported with systemic administration of IL-2
[361.
We used anti-T3 as the stimulus for T cells in our studies
since the T3 antigen complex is noncovalently associated with
the T cell antigen receptor [37, 38]. The T3 antigen is involved
in the transduction of activating signals initiated by antigens or
mitogens [37—39]. Activation via the T3 antigen also leads to
clonal expansion of all human peripheral blood T cells [401.
Moreover, anti-T3 is currently used as an anti-rejection agent in
organ graft recipients and can induce, at least in vitro, cytolytic
activity and lymphokine production.
We examined the effects of CSA, MP and 6-MP on anti-T3
associated activation since these agents represent the bulwark
of immunosuppressive agents used in clinical transplanation,
We reasoned that we might be able to appreciate their relative
inhibitory activity by testing all three agents in parallel. It is
noteworthy that the immunosuppressants were tested for their
activity at drug concentrations that are readily achieved in
clinical practice.
Results from the current investigation indicate that CSA and
MP are effective and 6-MP is relatively ineffective in preventing
anti-T3 associated T cell activation. These differential effects of
CSA, MP and 6-MP appear to result from their sites of action on
the T cell activation pathway. CSA and MP inhibit early events
and 6-MP inhibits late events in T cell activation. Wiskocil et al
[41] have shown that CSA inhibits the expression of genes for
IL-2 and interferon, gamma in the Jurkat T cell line activated
with anti-CD3. Reed et a! [42] have shown that steroids inhibit
gene expression in peripheral blood lymphocytes activated with
anti-T3. Our studies show that whereas CSA and MP inhibit the
production of lymphokines, an event that occurs prior to new
DNA synthesis, 6-MP inhibits new DNA synthesis but not the
production of lymphokines.
Recent studies have implicated an increase in the concentra-
tion of intracellular free calcium as an intracellular signal for T
cell activation [39, 43]. We therefore examined whether the
inhibitory activity of CSA and MP was a consequence of their
effects on calcium homeostasis. We found that CSA and MP did
not inhibit anti-T3 mediated increases in the concentration of
intracellular free calcium in quin-2 loaded Jurkat T cells. In a
representative experiment, the concentration of intracellular
free calcium increased from a resting level of 107 nM to 1163
nM, 1181 nM and 1212 nM with anti-T3 alone, anti-T3 + MP
(1000 ng!ml) and anti-T3 + CSA (250 ng/ml), respectively.
Because the mobilization of calcium is dependent in part on the
hydrolysis of phostaphatidyl inositol-4, 5-biphosphate [44, 45],
our findings suggest that the site of action of CSA and MP are
distal to phosphatidyl inositol hydrolysis but proximal to the
expression of genes for IL-2 and interferon, gamma.
The ability of CSA and MP to inhibit the production of
lymphokines appears to contribute to their inhibitory effects on
the induction of cytolytic activity since several studies have
shown that lymphokines regulate cytolytic activity of cytotoxic
T cells and NK cells [16, 46]. Indeed, we found that CSA and
MP which inhibit lymphokine production also inhibit the induc-
tion of cytolytic activity, and 6-MP which does not inhibit
lymphokine production fails to inhibit the induction of cytolytic
activity.
The studies reported here do not offer any insight as to the
precise mechanism by which 6-MP inhibits the proliferative
response found with memory cells activated with anti-T3. Our
findings are consistent with the possibility that the site of action
of 6-MP is distal to the expression of genes for IL-2 or
interferon, gamma but proximal to events leading to new DNA
synthesis [47, 48].
The clinical implications of our study are twofold. The
observation that anti-T3 induced cytolytic activity and
lymphokine production provides support for the speculation
that re-rejection episodes and other adverse reactions are
consequences of anti-T3's ability to activate T cells. The finding
that CSA and MP are highly effective in inhibiting anti-T3
associated T cell activation provides experimental support for
therapeutic protocols that include the use of CSA and/or MP
along with anti-T3.
The current recommendation for anti-T3 usage (package
insert, Ortho Pharmaceuticals) in renal graft rejection includes
the administration of methyl prednisolone sodium succinate
(1.0 mg/kg) prior to anti-T3 and hydrocortisone sodium suc-
cinate (100 mg) 30 minutes after anti-T3. Additional recommen-
dations include a reduction in the dosage of azathioprine to 25
mg and either discontinuation or reduction in the dosage of
cyclosporine. Our studies support the clinical use of steroids
and raises some concern regarding the suggestion to discon-
tinue CSA. Although controlled clinical trials are required to
settle the issue whether the use of CSA along with ariti-T3 will
reduce re-rejection episodes and other adverse side reactions, it
is clear at this stage that, in vitro, CSA or MP are more effective
than 6-MP in inhibiting anti-T3 associated activation of periph-
eral blood mononuclear cells.
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